The Gamaleya Center is ready to submit documents to the Ministry of Health of Russia to obtain permits for trials of new platforms for vaccines against coronavirus, TASS reports with reference to Aleksandr Ginzburg, the director of the Center.
“To provide protection against new variants which may appear due to mutations, we are preparing new platforms that will contain antigens for several variants of the coronavirus. Now we have started the documents submission process to obtain a permit for trials,” he said.
Earlier, Denis Logunov, deputy director of the Gamaleya Center, reported that the researchers are considering the option of creating a polyvalent vaccine against the novel coronavirus infection based on several virus strains at once, e. g., delta and omicron.
On January 24, it became known that the Gamaleya Research Institute of Epidemiology and Microbiology received permission to conduct phase I-III clinical trials of Sputnik-M, a vaccine against coronavirus for children.